"Drug Industry" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
That segment of commercial enterprise devoted to the design, development, and manufacture of chemical products for use in the diagnosis and treatment of disease, disability, or other dysfunction, or to improve function.
- Drug Industry
- Industry, Pharmaceutic
- Industries, Pharmaceutic
- Pharmaceutic Industries
- Pharmaceutic Industry
- Industry, Drug
- Drug Industries
- Industries, Drug
- Industry, Pharmaceutical
- Industries, Pharmaceutical
- Pharmaceutical Industries
- Pharmaceutical Industry
Below are MeSH descriptors whose meaning is more general than "Drug Industry".
Below are MeSH descriptors whose meaning is more specific than "Drug Industry".
This graph shows the total number of publications written about "Drug Industry" by people in this website by year, and whether "Drug Industry" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
|Year||Major Topic||Minor Topic||Total|
To return to the timeline, click here.
Below are the most recent publications written about "Drug Industry" by people in Profiles.
Crystal and Particle Engineering - An Indispensable Tool for Developing and Manufacturing Quality Pharmaceutical Products. Pharm Res. 2022 12; 39(12):3041-3045.
Evaluation of Industry Payments to US Advanced Practice Clinicians in 2021. JAMA Netw Open. 2022 11 01; 5(11):e2242869.
Promotional Payments to Medical Oncologists and Urologists and Prescriptions for Abiraterone and Enzalutamide. Urology. 2022 03; 161:50-58.
Combination therapy patents: a new front in evergreening. Nat Biotechnol. 2021 12; 39(12):1504-1510.
Decreasing utilization and increasing prices of brand-name oral contraceptive pills: Implications to societal costs and market competition. PLoS One. 2020; 15(6):e0234463.
Recent Advances in Co-processed APIs and Proposals for Enabling Commercialization of These Transformative Technologies. Mol Pharm. 2020 07 06; 17(7):2232-2244.
Rationale, Opportunities, and Reality of Biosimilar Medications. N Engl J Med. 2018 May 24; 378(21):2036-2044.
The Receipt of Industry Payments is Associated With Prescribing Promoted Alpha-blockers and Overactive Bladder Medications. Urology. 2018 Jul; 117:50-56.
The Sunshine Act and oncology: Lessons learned from urology. Semin Oncol. 2017 08; 44(4):265-266.
Pharmaceuticals and Public Health. JAMA. 2016 Nov 22; 316(20):2083-2084.